Thanks @Quitman for that post.
With Relyvrio out of the way. Basically leaves ourselves v Riluzole and Radicava. Riluzole increases median survival by up to 19 months .
Radicava costs $145 K PY . Short half live. 6 months median survival . Folks, that is our opposition now. PAA are now in a unique situation of saying to BP this is what we want in $. That's my read.
Kpax
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
14.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $68.92M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 7000 | 14.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 14.0¢ | 19364 | 1 |
View Market Depth
| Last trade - 10.03am 16/09/2025 (20 minute delay) ? |
| NUZ (ASX) Chart |
Day chart unavailable